AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18562772
Drug: Carbohydrate gel
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate gel (0.24 g/kg body mass)
Trial: 12799094
Drug: Telmisartan (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (40 mg daily for 2 weeks, increased to 80 mg if BP remained >/=130/85 mm Hg)
Trial: 12799094
Drug: Telmisartan (titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (titration from 40 mg to 80 mg)
Trial: 2227222
Drug: Gallopamil slow
RxNorm normalized name: gallopamil
DrugBank: Gallopamil (DB12923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallopamil slow release (100 mg, twice daily)
Trial: 2227222
Drug: Gallopamil immediate
RxNorm normalized name: gallopamil
DrugBank: Gallopamil (DB12923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallopamil immediate release (50 mg, four times daily)
Trial: 337985
Drug: Oral droperidol
RxNorm normalized name: Droperidol
DrugBank: Droperidol (DB00450)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral droperidol plus diazepam
Trial: 337985
Drug: Droperidol syrup
RxNorm normalized name: Droperidol
DrugBank: Droperidol (DB00450)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Droperidol syrup
Trial: 28521109
Drug: 22,600 ppm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22,600 ppm fluoride varnish, toothbrush, a 50-mL tube of 1,450 ppm fluoride toothpaste, and standardized prevention advice
Trial: 23332800
Drug: yoghurt enriched
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: yoghurt enriched with 3 g n‐3 LC‐PUFA/d
Trial: 23332800
Drug: yoghurt enriched
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: yoghurt enriched with 0.8 g n‐3 LC‐PUFA/d
Trial: 18053049
Drug: Phosphatidylcholine/sodium deoxycholate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphatidylcholine/sodium deoxycholate preparation
Trial: 16427861
Drug: Cold-blood cardioplegia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold-blood cardioplegia enriched with N-acetylcysteine (50 mg per kilogram of body weight)
Trial: 9126183
Drug: UP +
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UP + CB + weekly chlorhexidine rinse (CHX)
Trial: 8463520
Drug: Pentoxifylline 400
RxNorm normalized name: pentoxifylline 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline 400 mg tid for 12 weeks
Trial: 3948897
Drug: Glucagon (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucagon (1 mg bolus followed by 2 mg/h continuous infusion for 8 h)
Trial: 15765628
Drug: Continuous estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous estradiol 1 mg/day plus intermittent norgestimate 90 microg/day
Trial: 6793276
Drug: Systemically given
RxNorm normalized name: TITANIUM DIOXIDE 7.75 g in 100 mL / ZINC OXIDE 10 g in 100 mL TOPICAL CREAM [Give Me Shade Sunscreen Broad Spectrum SPF 30]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemically given antibiotics
Trial: 24521108
Drug: Pramipexole 0.5
RxNorm normalized name: pramipexole 0.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole 0.5 mg
Trial: 26765470
Drug: Therapeutic vaccine
RxNorm normalized name: COVID-19 Therapeutic Vaccine - Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic vaccine (YIC)
Trial: 24844551
Drug: Topical cooling
RxNorm normalized name: Castiva Cooling Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cooling with 4°C saline (Group I)
Trial: 24844551
Drug: Mild hypothermic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild hypothermic cardiopulmonary bypass (28‐32°C) without topical cooling (Group II)
Trial: 22540524
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg daily for three months (after initial oral bolus of 300 mg) together with aspirin 75 mg
Trial: 22540524
Drug: Aspirin 75
RxNorm normalized name: aspirin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 75 mg daily alone
Trial: 19595629
Drug: Dopaminergic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopaminergic treatment (pramipexole)
Trial: 19595629
Drug: Pre-treatment condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment condition (no dopaminergic treatment)
Trial: 16261945
Drug: Sabal-urtica preparation
RxNorm normalized name: Urtica preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sabal-urtica preparation PRO 160/120
Trial: 12123338
Drug: GEP (gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEP (gemcitabine 1000 mg/m2, epirubicin 90 mg/m2, paclitaxel 175 mg/m2)
Trial: 12123338
Drug: EP (epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EP (epirubicin 90 mg/m2, paclitaxel 175 mg/m2)
Trial: 12123338
Drug: Epirubicin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin alone (90 mg/m2)
Trial: 9021203
Drug: 3.375 g
RxNorm normalized name: Zosyn 3.375 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.375 g of piperacillin-tazobactam intravenously every 6 hours
Trial: 9021203
Drug: 4.5 g
RxNorm normalized name: Zosyn 4.5 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5 g of piperacillin-tazobactam intravenously every 8 hours
Trial: 9021203
Drug: 3.1 g
RxNorm normalized name: ticarcillin/K clavulanate 3.1 gram INTRAVEN VIAL (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.1 g of ticarcillin-clavulanate intravenously every 6 hours
Trial: 9021203
Drug: 3.0 g
RxNorm normalized name: LACTIC ACID 23.0 g in 1 L TOPICAL SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 g of ampicillin-sulbactam intravenously every 6 hours
Trial: 3351705
Drug: Locally prepared
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locally prepared milk‐free formulation (group A)
Trial: 3351705
Drug: Spray dried
RxNorm normalized name: peptone,dried
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spray dried commercial cow's milk formula (group B)
Trial: 26536315
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral emtricitabine/tenofovir disoproxil fumarate for HIV prevention
Trial: 26536315
Drug: Community and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community and partner discouragement regarding the study pill
Trial: 26536315
Drug: Limited acceptability
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Limited acceptability of the pill's attributes
Trial: 24637965
Drug: Low-protein experimental
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-protein experimental formula (EXPL) with 1.65 g of protein/100 kcal
Trial: 24637965
Drug: Control formula
RxNorm normalized name: Anti Acne Control Formula Top
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control formula (CTRL) with 2.7 g of protein/100 kcal
Trial: 22231734
Drug: Cevimeline 30
RxNorm normalized name: Cevimeline 30mg Oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cevimeline 30 mg orally 3 times daily for 6 weeks
Trial: 22231734
Drug: Placebo orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally 3 times daily for 6 weeks
Trial: 16466011
Drug: Fasting insulin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting insulin, IL-6, TNFalpha, and HOMA-IR index in type 2 diabetic patients
Trial: 10707793
Drug: Rituximab 375
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 375 mg/m2/week for 4 weeks
Trial: 10170451
Drug: Pressurised metered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressurised metered dose inhaler (pMDI)
Trial: 8113480
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (B)
Trial: 8113480
Drug: Information-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information-based therapy (A1)
Trial: 3533340
Drug: Pharmacological ionisation
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological ionisation with pirprofen (two-dose levels)
Trial: 27566696
Drug: 25 μg vaginal
RxNorm normalized name: Mycelex-G Vaginal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 μg vaginal misoprostol
Trial: 23812762
Drug: Alcohol (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.6 g/kg for men, 0.55 g/kg for women)
Trial: 16439370
Drug: Fondaparinux 2.5
RxNorm normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fondaparinux 2.5 mg subcutaneously once daily for six to 14 days
Trial: 14749738
Drug: Neither supplement
RxNorm normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neither supplement
Trial: 9403285
Drug: Mefloquine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine with food (750 mg)
Trial: 9403285
Drug: Mefloquine without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine without food (750 mg)
Trial: 7912285
Drug: Intradermal injections
RxNorm normalized name: Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injections of di‐Lex (III3FucnLc4) for 6 months
Trial: 7912285
Drug: Intradermal injections
RxNorm normalized name: Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injections of tumor associated carbohydrate antigen (TCA) for 6 months
Trial: 7912285
Drug: Intradermal injections
RxNorm normalized name: Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injections of monomeric Lex
Trial: 29706321
Drug: Resveratrol (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol (150 mg/day)
Trial: 28898473
Drug: Prucalopride (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prucalopride (4 mg oral)
Trial: 26990378
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin degludec (IDeg) add-on to liraglutide
Trial: 16626797
Drug: Proactive telephone-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proactive telephone-based peer counseling intervention with up to 6 counseling calls and nicotine replacement therapy (NRT) patches if prepared to quit smoking
Trial: 16626797
Drug: Demographic variables
RxNorm normalized name: Ferric carbonate, ferric hydroxide, ferrous hydroxide (variable mixture)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demographic variables (females, White), higher daily smoking rate, poorer perceived health and moderate perceived risk of smoking
Trial: 1716810
Drug: Salmonella typhi
RxNorm normalized name: Salmonella Typhi Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmonella typhi Ty21a/V. cholerae Inaba (EX210) vaccine
Trial: 29898692
Drug: Twice-weekly sessions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly sessions of protocolized interpersonal psychotherapy (IPT)
Trial: 29898692
Drug: Twice-weekly sessions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly sessions of cognitive behavioral therapy (CBT)
Trial: 29898692
Drug: Once-weekly sessions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly sessions of protocolized IPT and CBT
Trial: 26435055
Drug: Concomitant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant therapy (10-day regimen)
Trial: 26435055
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (10-day regimen)
Trial: 20536957
Drug: Self-monitoring of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-monitoring of blood glucose (SMBG) using premixed insulin lispro mixtures
Trial: 20536957
Drug: Self-monitoring of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-monitoring of blood glucose (SMBG) using basal insulin glargine
Trial: 18728175
Drug: Lifestyle modification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle modification + OCs + Metformin
Trial: 18728175
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment and placebo
Trial: 15717881
Drug: Lifestyle intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lifestyle intervention + insulin treatment (L+I)
Trial: 15717881
Drug: Insulin treatment
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin treatment alone (I)
Trial: 12187204
Drug: Transurethral resection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transurethral resection plus 100 mg epirubicin
Trial: 7869850
Drug: New generation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New generation combined oral contraceptives (OC)
Trial: 7869850
Drug: Oral protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral protein load in OC users
Trial: 787014
Drug: Fenoprofen calcium
RxNorm normalized name: Fenoprofen Calcium
DrugBank: Fenoprofen (DB00573)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenoprofen calcium (200, 400, or 600 mg)
Trial: 787014
Drug: Propoxyphene napsylate
RxNorm normalized name: Propoxyphene Napsylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propoxyphene napsylate (50, 100, or 150 mg)
Trial: 31495887
Drug: β-blocker use
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: β-blocker use (eGFR >60)
Trial: 31495887
Drug: β-blocker use
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: β-blocker use (eGFR 30-60)
Trial: 31495887
Drug: β-blocker use
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: β-blocker use (eGFR <30)
Trial: 25233649
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of acupuncture at Xiaojie point and tendon regulation manipulation
Trial: 20113920
Drug: HPV vaccine
RxNorm normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV vaccine coadministered with dTpa-IPV
Trial: 20113920
Drug: HPV vaccine
RxNorm normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV vaccine alone
Trial: 20113920
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of HPV vaccine and dTpa-IPV
Trial: 10944100
Drug: Oral anticoagulants
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulants or aspirin after infrainguinal bypass surgery
Trial: 26636426
Drug: Group Cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Cognitive Processing Therapy - Cognitive only version (CPT-C)
Trial: 25939018
Drug: Group Present-Centered
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Present-Centered Therapy (PCT)
Trial: 22970177
Drug: Fully integrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fully integrated services (ANC, PMTCT, and HIV treatment services all delivered in the ANC clinic)
Trial: 22970177
Drug: Non-integrated services
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-integrated services (ANC clinics provided ANC and basic PMTCT services and referred clients to a separate HIV clinic for HIV treatment)
Trial: 20233625
Drug: CA/AA versus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CA/AA versus CC genotypes in C8092A in ERCC1
Trial: 15531753
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP200), 200 microg daily for 3 months
Trial: 11985942
Drug: Micronutrient-containing beverage
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient-containing beverage (12 oz daily for 6 weeks)
Trial: 11985942
Drug: Placebo (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (12 oz daily for 6 weeks)
Trial: 28665038
Drug: M. chamomilla
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M. chamomilla L., M. officinalis L. and tyndallized L. acidophilus (HA122) (Colimil® Plus®)
Trial: 28665038
Drug: M. chamomilla
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M. chamomilla L., M. officinalis L. and tyndallized L. acidophilus (HA122)
Trial: 21412266
Drug: Candesartan (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (12 mg per day)
Trial: 21412266
Drug: Candesartan (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (8 mg per day) plus amlodipine (2.5 mg per day)
Trial: 17634896
Drug: MML group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MML group (moxifloxacin 400 mg/d, metronidazole 400 mg twice daily, lansoprazole 30 mg twice daily)
Trial: 17634896
Drug: MAL group
RxNorm normalized name: maleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAL group (moxifloxacin 400 mg/d, amoxicillin 1 g twice daily, lansoprazole 30 mg twice daily)
Trial: 17634896
Drug: CML group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CML group (clarithromycin 500 mg twice daily, metronidazole 400 mg twice daily, lansoprazole 30 mg twice daily)
Trial: 17634896
Drug: CAL group
RxNorm normalized name: meningococcal group B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAL group (clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily, lansoprazole 30 mg twice daily)
Trial: 11722487
Drug: Topical skin
RxNorm normalized name: Betadine 7.5% Topical Skin Cleanser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical skin lipid mixture containing ceramide‐3 and patented nanoparticles
Trial: 11722487
Drug: Topical skin
RxNorm normalized name: Betadine 7.5% Topical Skin Cleanser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical skin lipid mixture in combination with topical corticosteroids
Trial: 11722487
Drug: Control (Topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Topical corticosteroids alone)
Trial: 372867
Drug: Diclofenac 25
RxNorm normalized name: diclofenac 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 25 mg q.i.d.
Trial: 372867
Drug: Aspirin 750
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 750 mg q.i.d.
Trial: 31989580
Drug: Behavioural change
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural change programme plus moisturizing creams
Trial: 28295451
Drug: GSK3050002 (0.1-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3050002 (0.1-20 mg kg-1)
Trial: 28295451
Drug: GSK3050002 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3050002 (5 mg kg-1 and higher)
Trial: 21193422
Drug: 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg of vitamin K(1)
Trial: 21193422
Drug: 150 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 μg of vitamin K(1)
Trial: 21193422
Drug: 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg of vitamin K(1)
Trial: 15022805
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg cholestyramine-bound diclofenac (2 x 1 capsule Voltaren resinate) daily for 14 days
Trial: 15022805
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg cholestyramine-bound diclofenac (1 x 1 capsule) daily for 14 days
Trial: 15022805
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose (75 mg)
Trial: 11255384
Drug: Nortriptyline (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline (target steady-state level, 75-125 ng/mL) (n = 27)
Trial: 11255384
Drug: Nortriptyline-lithium combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline-lithium combination (target steady-state level, 0.5-0.9 mEq/L) (n = 28)
Trial: 9544650
Drug: Adjunctive mitomycin
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjunctive mitomycin C (MMC)
Trial: 9544650
Drug: No adjunctive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjunctive mitomycin C (SGTP control)
Trial: 2582838
Drug: Fenoterol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol (400 micrograms, 600 micrograms, and 800 micrograms administered at 15-minute intervals, total dose 1.8 mg)
Trial: 31609667
Drug: IPL +
RxNorm normalized name: IPL-344
DrugBank: IPL-344 (DB16958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPL + RF combination therapy
Trial: 31476481
Drug: Duloxetine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (60 mg, 2 doses: 2 hours before and 24 hours after surgery)
Trial: 31476481
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 doses, 2 hours before and 24 hours after surgery)